Osteoporosis drug switch: can zoledronate stop bone loss after denosumab?
NCT ID NCT05655013
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 30 times
Summary
This study looks at whether the drug zoledronate can prevent bone loss in postmenopausal women who stop taking denosumab, a common osteoporosis treatment. About 200 women who have been on denosumab for at least two years will receive zoledronate infusions at different times. The goal is to find the best way to keep bones strong and prevent fractures after switching treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS, POSTMENOPAUSAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Aarhus University Hospital
Aarhus, Denmark
Conditions
Explore the condition pages connected to this study.